{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:00:20Z","timestamp":1791928820067,"version":"4.3.4"},"reference-count":24,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"7","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2023,6,19]]},"DOI":"10.1167\/iovs.64.7.29","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T11:31:01Z","timestamp":1687174261000},"page":"29","source":"Crossref","is-referenced-by-count":10,"title":["Immune Checkpoint Inhibitor Therapy for Orbital and Ocular Adnexal Squamous Cell Carcinomas: International Society of Ocular Oncology President's Lecture, 2022"],"prefix":"10.1167","volume":"64","author":[{"given":"Bita","family":"Esmaeli","sequence":"first","affiliation":[{"name":"Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"issue":"10","key":"bib1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/bjophthalmol-2017-310956","article-title":"Report on the incidence of squamous cell carcinomas affecting the eyelids in England over a 15-year period (2000-2014)","volume":"102","author":"Wawrzynski","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"bib2","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0161-6420(99)90161-6","article-title":"Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmsted County, Minnesota","volume":"106","author":"Cook","year":"1999","journal-title":"Ophthalmology"},{"issue":"5","key":"bib3","first-page":"585","article-title":"Periocular squamous cell carcinoma","volume":"34","author":"Thosani","year":"2008","journal-title":"Dermatol Surg"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"issue":"12","key":"bib5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IIO.0000000000000271","article-title":"Targeted biological drugs and immune check point inhibitors for locally advanced or metastatic cancers of the conjunctiva, eyelid, and orbit","volume":"59","author":"Esmaeli","year":"2019","journal-title":"Int Ophthalmol Clin"},{"issue":"2","key":"bib11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"bib12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"bib13","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"17","key":"bib14","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"bib15","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"bib16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"6","key":"bib17","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1167\/iovs.19-26894","article-title":"PD-L1\/PD1 Expression, composition of tumor-associated immune infiltrate, and HPV status in conjunctival squamous cell carcinoma","volume":"60","author":"Nagarajan","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1230","key":"bib18","first-page":"2","article-title":"Use of cemiplimab in locally advanced cutaneous squamous cell carcinoma","volume":"10","author":"Schaffer","year":"2020","journal-title":"J Clin Case Rep"},{"issue":"10","key":"bib19","doi-asserted-by":"publisher","first-page":"13030","DOI":"10.5070\/D32610050463","article-title":"Successful treatment of recurrent advanced cutaneous squamous cell carcinoma with cemiplimab","volume":"26","author":"Cervantes","year":"2020","journal-title":"Dermatol Online J"},{"issue":"3","key":"bib20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/bjophthalmol-2021-319417","article-title":"Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma","volume":"107","author":"Goldfarb","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"bib21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"bib22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"bib23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jaad.2021.01.048","article-title":"Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma","volume":"85","author":"Shalhout","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"bib24","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41416-020-01044-8","article-title":"Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)","volume":"123","author":"Hanna","year":"2020","journal-title":"Br J Cancer"},{"key":"bib7","article-title":"FDA labeling information\u2014YERVOY","author":"US Food and Drug Administration","year":"2015"},{"key":"bib8","article-title":"FDA labeling information\u2014OPDIVO","author":"US Food and Drug Administration","year":"2017"},{"key":"bib9","article-title":"FDA labeling information\u2014KEYTRUDA","author":"US Food and Drug Administration","year":"2017"},{"key":"bib10","article-title":"FDA labeling information\u2014BAVENCIO","author":"US Food and Drug Administration","year":"2017"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2785712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:42Z","timestamp":1791927102000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2785712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.64.7.29","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,19]]}}}